[1] |
Global initiative for chronic obstructive lung disease. Global strategy for prevention, diagnosis, and management of COPD (2021 REPORT)[EB/OL]. https://goldcopdorg/2021-gold-reports/, 2021-11-17.
|
[2] |
World Health Organization Burden of COPD. The top 10 causes of death[EB/OL]. https://wwwwhoint/zh/news-room/fact-sheets/detail/the-top-10-causes-of-death, 2021-11-17.
|
[3] |
Miravitlles M, Calle M, Molina J, et al. Spanish COPD guidelines (GesEPOC): Pharmacological treatment of stable COPD[J]. Aten Primaria, 2012, 44(7):425-437.
doi: 10.1016/j.aprim.2012.04.005
URL
|
[4] |
Zbozinkova Z, Barczyk A, Tkacova R, et al. POPE study: Rationale and methodology of a study to phenotype patients with COPD in central and eastern Europe[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11:611-622.
|
[5] |
Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase[J]. Arch Bronconeumol, 2017, 53(6):324-335.
doi: 10.1016/j.arbres.2017.03.018
URL
|
[6] |
Golpe R, Suárez-Valor M, Martín-Robles I, et al. Mortality in COPD patients according to clinical phenotypes[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13:1433-1439.
doi: 10.2147/COPD
URL
|
[7] |
姚锡娟, 马倩, 刘韩韩, 等. 慢性阻塞性肺疾病不同临床表型患病率及临床特征的Meta分析[J]. 重庆医学, 2021, 50(1):126-132.
|
[8] |
黄宇婷, 刘翱. HRCT定量测量与慢性阻塞性肺疾病表型的关系[J]. 中华肺部疾病杂志(电子版), 2015, 8(2):251-253.
|
[9] |
李辉安, 师美娟, 沈聪, 等. 基于体素的COPD早期诊断与CT肺功能定量评估[J]. 西安交通大学学报(医学版), 2019, 40(2):187-192.
|
[10] |
Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping[J]. J Allergy Clin Immunol, 2018, 141(6):1961-1971.
doi: S0091-6749(18)30332-4
pmid: 29884286
|
[11] |
Kirby M, Tanabe N, Tan WC, et al. Total airway count on computed tomography and the risk of chronic obstructive pulmonary disease progression. findings from a population-based study[J]. Am J Respir Crit Care Med, 2018, 197(1):56-65.
doi: 10.1164/rccm.201704-0692OC
URL
|
[12] |
Fan L, Xia Y, Guan Y, et al. Characteristic features of pulmonary function test, CT volume analysis and MR perfusion imaging in COPD patients with different HRCT phenotypes[J]. Clin Respir J, 2014, 8(1):45-54.
doi: 10.1111/crj.12033
pmid: 23711228
|
[13] |
王述红, 何正光, 罗晓斌, 等. 慢性阻塞性肺疾病患者胸部高分辨率CT指标分型特征[J]. 现代医院, 2016, 16(4):514-517.
|
[14] |
谭博. 慢性阻塞性肺疾病患者胸部HRCT表型的肺功能和血清生物标志物特征研究[D]. 太原: 山西医科大学, 2016.
|
[15] |
Fletcher C, Peto R. The natural history of chronic airflow obstruction[J]. Br Med J, 1977, 1(6077):1645-1648.
|
[16] |
Ji W, Lim MN, Bak SH, et al. Differences in chronic obstructive pulmonary disease phenotypes between non-smokers and smokers[J]. Clin Respir J, 2018, 12(2):666-673.
doi: 10.1111/crj.12577
pmid: 27805311
|
[17] |
Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary disease in adult life[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13:683-693.
doi: 10.2147/COPD
URL
|
[18] |
Cho J, Lee CH, Hwang SS, et al. Risk of acute exacerbations in chronic obstructive pulmonary disease associated with biomass smoke compared with tobacco smoke[J]. BMC Pulm Med, 2019, 19(1):68.
doi: 10.1186/s12890-019-0833-7
pmid: 30902075
|
[19] |
Zhao D, Zhou Y, Jiang C, et al. Small airway disease: A different phenotype of early stage COPD associated with biomass smoke exposure[J]. Respirology, 2018, 23(2):198-205.
doi: 10.1111/resp.13176
pmid: 28906034
|
[20] |
Adachi H, Derevnina L, Kamoun S. NLR singletons, pairs, and networks: Evolution, assembly, and regulation of the intracellular immunoreceptor circuitry of plants[J]. Curr Opin Plant Biol, 2019, 50:121-131.
doi: S1369-5266(18)30154-7
pmid: 31154077
|
[21] |
Mincham KT, Bruno N, Singanayagam A, et al. Our evolving view of neutrophils in defining the pathology of chronic lung disease[J]. Immunology, 2021, 164(4):701-721.
doi: 10.1111/imm.13419
pmid: 34547115
|
[22] |
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2016, 138(1):16-27.
doi: 10.1016/j.jaci.2016.05.011
pmid: 27373322
|
[23] |
Hughes MJ, Sapey E, Stockley R. Neutrophil phenotypes in chronic lung disease[J]. Expert Rev Respir Med, 2019, 13(10):951-967.
doi: 10.1080/17476348.2019.1654377
URL
|
[24] |
Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: A surrogate marker for airway eosinophilia in stable COPD[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11:1495-1504.
doi: 10.2147/COPD
URL
|
[25] |
Antus B, Barta I. Blood eosinophils and exhaled nitric oxide: Surrogate biomarkers of airway eosinophilia in stable COPD and exacerbation[J]. Biomedicines, 2022, 10(9):2128.
doi: 10.3390/biomedicines10092128
URL
|
[26] |
David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD:From an inflammatory marker to a treatable trait[J]. Thorax, 2021, 76(2):188-195.
doi: 10.1136/thoraxjnl-2020-215167
URL
|
[27] |
Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): A multicentre, randomised, controlled, open-label, non-inferiority trial[J]. Lancet Respir Med, 2019, 7(8):699-709.
doi: 10.1016/S2213-2600(19)30176-6
pmid: 31122894
|
[28] |
王晓娟, 方向阳. 慢性阻塞性肺疾病全球倡议2019:慢性阻塞性肺疾病诊断、治疗与预防全球策略解读[J]. 中国全科医学, 2019, 22(18):2141-2149.
doi: 10.12114/j.issn.1007-9572.2019.00.064
|
[29] |
Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis[J]. Am J Respir Crit Care Med, 2020, 201(9):1078-1085.
doi: 10.1164/rccm.201908-1550OC
URL
|
[30] |
Jabarkhil A, Moberg M, Janner J, et al. Elevated blood eosinophils in acute COPD exacerbations: Better short- and long-term prognosis[J]. Eur Clin Respir J, 2020, 7(1):1757274.
doi: 10.1080/20018525.2020.1757274
URL
|
[31] |
Kandemir Y, Doˇgan NÖ, Yaka E, et al. Clinical characteristics of neutrophilic, eosinophilic and mixed-type exacerbation phenotypes of COPD[J]. Am J Emerg Med, 2021, 45:237-241.
doi: 10.1016/j.ajem.2020.08.044
pmid: 33041140
|